Cerner20Campus-HITN.jpg

Cerner on Thursday announced the completion of its purchase of Kantar Health for $375 million in cash – an acquisition it says will be a boost to its expanded efforts toward life sciences research capabilities .

WHY IT MATTERS
Kantar Health’s analytics expertise spans a broad selection of therapeutic areas: Alzheimer’s, cancers, rare diseases and much more . Its tools and policy expertise have been used by companies across the Pharma and life sciences businesses .

Cerner says combining this study and consulting bona fides with its real-world information stores and portfolio of technology can better help companies and research groups to develop new therapeutics and improve health, wellness and treatment outcomes .

With the conclusion of the deal, which was announced in December 2020, Kantar Health’s global team – including its consulting and research solutions and customers – will combine Cerner’s Strategic Growth business, according to the firm .

Lynnette Cooke will continue to lead the Kantar Health team and join the Cerner leadership.  

“Kantar Health and Cerner’s Strategic Development business have a great deal in common, starting with a vision to advance patient care around the world, ” explained Cooke in a press statement. “Culturally, we share the same values when it comes to how we develop our people, our offer and our customer base. “

THE LARGER TREND
With the purchase , Cerner intends to further build out its Cerner Learning Health Network client consortium. First launched in 2019 in collaboration with Duke Clinical Research Institute, the system aims to offer medical researchers quicker and easier access to data that could help them innovate new approaches to wellness .

1 recent addition to the Learning Health Network consortium was a December 2020 investment in Elligo Health Research, which Cerner said would offer additional clinical trial funds to rural and community hospitals, and physician practices.

Especially Cerner hopes to bolster the cooperation between care providers and the pharmaceutical sector – enabling life sciences researchers to uncover more insights using distinguished RWD resources for complex clinical research questions.

Today, the consortium comprises 92 million patients and 776 million clinical encounters ; Cerner hopes the addition of Kantar Health will broaden engagement with life sciences companies for funded research studies and development of new therapeutics.

ON THE RECORD
“The promise of real-world evidence to electricity drug discovery is right in front of us, ” said Cerner President Donald Trigg in a statement. “Kantar Health is an important next step in building out the capabilities our growing community of provider clients need to fundamentally change the time and cost for clinical trials. “

“Our collective capabilities and assets will enable the acceleration of innovation and elevate our experience in addressing the most complex clinical study questions changing the way health care is developed and delivered , ” added Cooke.

Twitter: @MikeMiliardHITN
Email the author : mike.miliard@himssmedia.com

Healthcare IT News is a HIMSS publication .

Leave a Reply

Your email address will not be published. Required fields are marked *